Revolutionizing CLL Treatment: The Impact of New Fixed Duration and Continuous Regimens on Patient Care
CLL Treatment in 2025: Navigating Patient Choice, BTK Inhibitors, and the Shifting Landscape of Care Table of Contents CLL Treatment in 2025: Navigating Patient Choice, BTK Inhibitors, and the Shifting Landscape of Care Patient Choice and Treatment Duration BTK Inhibitors: Ibrutinib, Acalabrutinib, and Zanubrutinib The Role of Continuous Therapy vs. Fixed-Duration Approaches Doublet Therapies: Ibrutinib/Venetoclax … Read more